Corcept Therapeutics Statistics
Share Statistics
Corcept Therapeutics has 104.78M shares outstanding. The number of shares has increased by 1.22% in one year.
| Shares Outstanding | 104.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.27% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 90.25M |
| Failed to Deliver (FTD) Shares | 136 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 15.72M, so 15% of the outstanding shares have been sold short.
| Short Interest | 15.72M |
| Short % of Shares Out | 15% |
| Short % of Float | 17.42% |
| Short Ratio (days to cover) | 19.17 |
Valuation Ratios
The PE ratio is 31.69 and the forward PE ratio is 33.02. Corcept Therapeutics's PEG ratio is 0.12.
| PE Ratio | 31.69 |
| Forward PE | 33.02 |
| PS Ratio | 6.97 |
| Forward PS | 5.2 |
| PB Ratio | 6.64 |
| P/FCF Ratio | 26.51 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Corcept Therapeutics has an Enterprise Value (EV) of 3.23B.
| EV / Earnings | 30.41 |
| EV / Sales | 6.69 |
| EV / EBITDA | 29.8 |
| EV / EBIT | 30.09 |
| EV / FCF | 25.44 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.
| Current Ratio | 4.39 |
| Quick Ratio | 4.31 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.03 |
| Cash Flow / Debt | 841.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on capital (ROIC) is 18.04%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 0.17% |
| Return on Capital (ROIC) | 18.04% |
| Revenue Per Employee | 1.37M |
| Profits Per Employee | 301.53K |
| Employee Count | 352 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | 18.42M |
| Effective Tax Rate | 0.15 |
Stock Price Statistics
The stock price has increased by 109.75% in the last 52 weeks. The beta is 0.46, so Corcept Therapeutics's price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | 109.75% |
| 50-Day Moving Average | 54.62 |
| 200-Day Moving Average | 38.93 |
| Relative Strength Index (RSI) | 46.15 |
| Average Volume (20 Days) | 962.20K |
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 482.38M and earned 106.14M in profits. Earnings per share was 1.02.
| Revenue | 482.38M |
| Gross Profit | 475.89M |
| Operating Income | 107.28M |
| Net Income | 106.14M |
| EBITDA | 108.32M |
| EBIT | 107.28M |
| Earnings Per Share (EPS) | 1.02 |
Balance Sheet
The company has 135.55M in cash and 151.00K in debt, giving a net cash position of 135.40M.
| Cash & Cash Equivalents | 135.55M |
| Total Debt | 151.00K |
| Net Cash | 135.40M |
| Retained Earnings | 402.53M |
| Total Assets | 784.26M |
| Working Capital | 340.76M |
Cash Flow
In the last 12 months, operating cash flow was 127.04M and capital expenditures -139.00K, giving a free cash flow of 126.90M.
| Operating Cash Flow | 127.04M |
| Capital Expenditures | -139.00K |
| Free Cash Flow | 126.90M |
| FCF Per Share | 1.23 |
Margins
Gross margin is 98.66%, with operating and profit margins of 22.24% and 22%.
| Gross Margin | 98.66% |
| Operating Margin | 22.24% |
| Pretax Margin | 25.82% |
| Profit Margin | 22% |
| EBITDA Margin | 22.46% |
| EBIT Margin | 22.24% |
| FCF Margin | 26.31% |
Dividends & Yields
CORT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.98% |
| FCF Yield | 2.35% |
Analyst Forecast
The average price target for CORT is $77, which is 49.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $77 |
| Price Target Difference | 49.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 25.17 |
| Piotroski F-Score | 6 |